SNTA, Synta Pharmaceuticals Corp.
SNTA is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease.
SNTA reported that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer (NSCLC) were presented at the International Association for the Study of Lung Cancer (IASLC) 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting. The trial is ongoing; final results are expected later this year.
Read the rest of Synta's drug on clinical trial plus other news at: http://drstockpick.com/?p=17878